Literature DB >> 21216670

Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.

François Chollet1, Jean Tardy, Jean-François Albucher, Claire Thalamas, Emilie Berard, Catherine Lamy, Yannick Bejot, Sandrine Deltour, Assia Jaillard, Philippe Niclot, Benoit Guillon, Thierry Moulin, Philippe Marque, Jérémie Pariente, Catherine Arnaud, Isabelle Loubinoux.   

Abstract

BACKGROUND: Hemiplegia and hemiparesis are the most common deficits caused by stroke. A few small clinical trials suggest that fluoxetine enhances motor recovery but its clinical efficacy is unknown. We therefore aimed to investigate whether fluoxetine would enhance motor recovery if given soon after an ischaemic stroke to patients who have motor deficits.
METHODS: In this double-blind, placebo-controlled trial, patients from nine stroke centres in France who had ischaemic stroke and hemiplegia or hemiparesis, had Fugl-Meyer motor scale (FMMS) scores of 55 or less, and were aged between 18 years and 85 years were eligible for inclusion. Patients were randomly assigned, using a computer random-number generator, in a 1:1 ratio to fluoxetine (20 mg once per day, orally) or placebo for 3 months starting 5-10 days after the onset of stroke. All patients had physiotherapy. The primary outcome measure was the change on the FMMS between day 0 and day 90 after the start of the study drug. Participants, carers, and physicians assessing the outcome were masked to group assignment. Analysis was of all patients for whom data were available (full analysis set). This trial is registered with ClinicalTrials.gov, number NCT00657163.
FINDINGS: 118 patients were randomly assigned to fluoxetine (n=59) or placebo (n=59), and 113 were included in the analysis (57 in the fluoxetine group and 56 in the placebo group). Two patients died before day 90 and three withdrew from the study. FMMS improvement at day 90 was significantly greater in the fluoxetine group (adjusted mean 34·0 points [95% CI 29·7-38·4]) than in the placebo group (24·3 points [19·9-28·7]; p=0·003). The main adverse events in the fluoxetine and placebo groups were hyponatraemia (two [4%] vs two [4%]), transient digestive disorders including nausea, diarrhoea, and abdominal pain (14 [25%] vs six [11%]), hepatic enzyme disorders (five [9%] vs ten [18%]), psychiatric disorders (three [5%] vs four [7%]), insomnia (19 [33%] vs 20 [36%]), and partial seizure (one [<1%] vs 0).
INTERPRETATION: In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy enhanced motor recovery after 3 months. Modulation of spontaneous brain plasticity by drugs is a promising pathway for treatment of patients with ischaemic stroke and moderate to severe motor deficit. FUNDING: Public French National Programme for Clinical Research. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216670     DOI: 10.1016/S1474-4422(10)70314-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  255 in total

1.  Strategies for early stroke recovery: what lies ahead?

Authors:  Tomoko Kitago; Randolph S Marshall
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-01

2.  Experience-dependent expression of NPAS4 regulates plasticity in adult visual cortex.

Authors:  José Fernando Maya-Vetencourt; Ettore Tiraboschi; Dario Greco; Laura Restani; Chiara Cerri; Petri Auvinen; Lamberto Maffei; Eero Castrén
Journal:  J Physiol       Date:  2012-06-06       Impact factor: 5.182

Review 3.  Postoperative Cognitive Dysfunction: Minding the Gaps in Our Knowledge of a Common Postoperative Complication in the Elderly.

Authors:  Miles Berger; Jacob W Nadler; Jeffrey Browndyke; Niccolo Terrando; Vikram Ponnusamy; Harvey Jay Cohen; Heather E Whitson; Joseph P Mathew
Journal:  Anesthesiol Clin       Date:  2015-07-16

4.  Paradoxical Motor Recovery From a First Stroke After Induction of a Second Stroke: Reopening a Postischemic Sensitive Period.

Authors:  Steven R Zeiler; Robert Hubbard; Ellen M Gibson; Tony Zheng; Kwan Ng; Richard O'Brien; John W Krakauer
Journal:  Neurorehabil Neural Repair       Date:  2015-12-31       Impact factor: 3.919

Review 5.  The Specific Requirements of Neural Repair Trials for Stroke.

Authors:  Bruce H Dobkin; S Thomas Carmichael
Journal:  Neurorehabil Neural Repair       Date:  2015-09-10       Impact factor: 3.919

6.  Duration of Agitation, Fluctuations of Consciousness, and Associations with Outcome in Patients with Subarachnoid Hemorrhage.

Authors:  Michael E Reznik; Ali Mahta; J Michael Schmidt; Hans-Peter Frey; Soojin Park; David J Roh; Sachin Agarwal; Jan Claassen
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

7.  Neuronal plasticity and antidepressant actions.

Authors:  Eero Castrén; René Hen
Journal:  Trends Neurosci       Date:  2013-02-01       Impact factor: 13.837

Review 8.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 9.  Pediatric Stroke: Unique Implications of the Immature Brain on Injury and Recovery.

Authors:  Laura A Malone; Ryan J Felling
Journal:  Pediatr Neurol       Date:  2019-07-03       Impact factor: 3.372

Review 10.  Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Authors:  F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.